[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of California, Los Angeles\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":623},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,165,0,25,[9,47,68,96,124,153,180,203,230,260,282,310,335,361,381,401,422,443,463,495,519,541,559,584,603],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100614219","coaching-and-leadership-in-autism-support-settings-100614219",false,"NCT07276750","Coaching and Leadership in Autism Support Settings","CLASS","Inclusion Criteria:\n\n* Special or general education teachers, paraeducators, and other staff who provide direct instruction and\u002For behavioral support to autistic children during the school day (e.g., speech therapist, school psychologist).\n* Autistic children with:\n* a documented autism spectrum disorder diagnosis via school records (i.e., Individualized Education Program; IEP)\n* are enrolled with a participating educator\n* are in grades K-5\n* ages 5-12\n* Sutter Eyberg Student Behavior Inventory-Revised (SESBI-R) total score \\>=101\n* EDI sum score of \\>=8 at baseline\n\nExclusion Criteria:\n\n* SESBI-R total score \\\u003C101 (i.e. T score 51+)\n* EDI sum score \\\u003C8",true,"ALL","5 Years",{"count":21,"type":22},373,"ESTIMATED","INTERVENTIONAL",[25],"NA","Schools serve a large number of autistic children, yet face two critical gaps that stifle the delivery of evidence-based practices: 1) an intervention gap characterized by limited availability of evidence-based practices educators can use to address externalizing behaviors when they occur in the classroom; and 2) an implementation gap consisting of insufficient evidence-based practice fidelity and sustainment over time. To address these gaps, this project proposes a hybrid type 2 effectiveness-implementation trial that simultaneously tests: 1) the clinical effectiveness of an efficient, educator-delivered clinical intervention to reduce autistic children's externalizing behaviors (Research Units in Behavioral Interventions in Educational Settings; RUBIES), and 2) the implementation effectiveness of an organizational implementation strategy designed specifically to enhance sustainment of evidence-based practices in public schools (Helping Educational Leaders Mobilize evidence; HELM). Consistent with the National Institute of Mental Health (NIMH)'s experimental therapeutics approach, the project also examines the mechanisms through which RUBIES impacts clinical outcomes and through which HELM influences implementation outcomes. The proposed study directly responds to high priority research areas of the US Department of Health and Human Services Interagency Autism Coordinating Committee's Strategic Plan for Autism Research, which calls for expanded research on the translation of proven-efficacious interventions into the community, NIMH Strategic Priority 3.3 to test interventions for effectiveness in community practice settings, and NIMH Strategic Priority 4.2 to expedite adoption, sustained implementation, and continuous improvement of evidence-based mental health services. If successful, this study will have substantial public health impact because it will produce an effective intervention for a prevalent problem among a high impact population in schools across the United States of America and will determine how to sustain this (and other) intervention(s) with high fidelity, to the betterment of health.",[28],"Autism Spectrum Disorder (ASD)",[30,31,32,33],"implementation","schools","autism","behavior management","RECRUITING","2026-08-20",{"date":37,"type":38},"2026-08-21","ACTUAL",{"date":40,"type":38},"2026-02-01",{"date":42,"type":22},"2030-08-31",{"name":44,"class":45},"University of California, Los Angeles","OTHER",1,{"id":48,"slug":49,"hasResults":12,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":17,"sex":18,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":46},"100652946","measurement-and-determinants-of-diet-quality-in-older-adults-100652946","NCT07780708","Measurement and Determinants of Diet Quality in Older Adults","Validating Dietary Quality Measures and Exploring Barriers to Healthy Eating Among Older Adults in Los Angeles","Inclusion Criteria:\n\n* Participants eligible for enrollment in either the survey or interview component must meet the following criteria:\n\n  * Be 60 years of age or older\n  * Be a regular attendee (i.e., more than one visit) at L.A. County Food Rx produce distribution events\n  * Be able to communicate in English or Spanish, as these are the languages in which study materials and interviews are available\n  * Be able to provide informed consent and complete the brief study activities These criteria reflect the study's focus on older adults at increased risk for chronic disease due to food insecurity and poor diet quality. English and Spanish were selected based on the primary languages spoken at Food Rx distribution sites and the capacity of the study team to support accurate, culturally sensitive data collection.\n\nExclusion Criteria:\n\n* Individuals will be excluded if they:\n\n  * Are younger than 60 years old\n  * Are first-time attendees at the produce distribution site (i.e., not familiar with program operations)\n  * Are unable to understand or communicate in English or Spanish\n  * Are unable to provide informed consent or complete the questionnaires or interview due to cognitive or physical limitations Language and participation history were included as exclusion criteria to ensure participant familiarity with the setting and the ability to engage meaningfully in data collection. ose who cannot provide informed consent will be excluded in accordance with ethical research protections for vulnerable adults.","60 Years",{"count":56,"type":22},125,"OBSERVATIONAL","The goal of this observational study is to learn about dietary quality and barriers to healthy eating among older adults who participate in the Los Angeles County Food Rx Produce Distribution Program. The study will also evaluate whether a newer dietary assessment tool, the Global Diet Quality Questionnaire (GDQQ), performs similarly to an established dietary assessment tool, the Mediterranean Diet Scale (PREDIMED MDS), in measuring diet quality among adults aged 60 years and older.\n\nThe main questions it aims to answer are:\n\n* Is the GDQQ associated with diet quality scores measured by the PREDIMED Mediterranean Diet Scale?\n* Does the GDQQ predict self-reported body mass index (BMI) as well as or better than the PREDIMED Mediterranean Diet Scale?\n* What barriers and facilitators influence healthy eating and participation in produce distribution programs among older adults?\n\nParticipants will:\n\n* Complete questionnaires about their dietary habits, demographic characteristics, and food access experiences.\n* Complete two dietary quality assessment tools: the PREDIMED Mediterranean Diet Scale and the Global Diet Quality Questionnaire.\n* If randomly selected, participate in a one-time semi-structured interview to discuss healthy eating, food access, experiences with produce distribution events, and challenges to improving dietary quality.",[60],"None Volunteer","2026-08-19",{"date":37,"type":38},{"date":64,"type":38},"2026-02-26",{"date":66,"type":22},"2026-10",{"name":44,"class":45},{"id":69,"slug":70,"hasResults":12,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":12,"sex":18,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":23,"phases":80,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},"100568530","telerehabilitation-in-the-home-after-stroke-100568530","NCT06682429","Telerehabilitation In The Home After Stroke","Telerehabilitation In The Home After Stroke: A Randomized, Controlled, Assessor-Blind Clinical Trial","TR-2","Inclusion Criteria:\n\n1. Age 18-80 years at the time of randomization\n2. The index stroke was radiologically verified, due to ischemia or intracerebral hemorrhage (ICH), and had time of onset 120±30 days prior to randomization\n3. The stroke caused upper extremity deficits as defined by Action Research Arm Test score 18-44 (out of 57) at Baseline Visit 1\n4. Box \\& Block Test score with affected arm is ≥1 block in 60 seconds at Baseline Visit 1\n5. Able to successfully perform all 3 rehabilitation exercise test examples (simple commands) at Baseline Visit 1\n6. Informed consent and behavioral contract signed by the subject (i.e., no surrogate consent)\n\nExclusion Criteria:\n\n1. A major, active, coexistent neurological, psychiatric, or medical disease that reduces the likelihood that a subject will be able to comply with all study procedures\n2. Unable or unwilling to perform study procedures\u002Ftherapy, or expectation of noncompliance with study procedures\u002Ftherapy, or expectation that subject cannot participate in all study visits\n3. A diagnosis (apart from the index stroke) that substantially affects paretic arm function\n4. Severe depression, defined as Geriatric Depression Scale Score \\>10\u002F15 at Baseline Visit 1\n5. Significant cognitive impairment, defined as Montreal Cognitive Assessment score \\\u003C22 \\[a lower score is permitted if due to aphasia and allowed by the site PI\\]\n6. Deficits in communication that interfere with reasonable study participation\n7. Severe UE spasticity, defined as presence of contracture or modified Ashworth Scale score=4 in either biceps or pectoralis\n8. Modified Rankin Scale score was \\>2 prior to the index stroke\n9. A new symptomatic stroke has occurred since the index stroke, or a separate stroke occurred within 30 days prior to the index stroke\n10. Lacking visual acuity, with or without corrective lens, of 20\u002F50 or better in at least one eye\n11. Life expectancy \\\u003C 9 months\n12. Pregnant; women of child-bearing potential must have a negative pregnancy test\n13. Botulinum toxin to the paretic arm: received in the prior 3 months OR expected by the 8-Month Visit\n14. Concurrent enrollment in another therapy-based investigational study where the duration of the investigational therapy's activity is likely to occur during the subject's participation in the study\n15. Subject lacks sufficient English or Spanish to comply with study procedures and TR instructions\n16. Expectation that subject will not have a single domicile address during the 6 weeks of therapy that is within 1.5-hr drive of the central study site \\[this can be waived at the discretion of the site PI\\]\n17. Contraindication to MRI\n18. On isolation precautions, e.g., due to active COVID-19","18 Years","80 Years",{"count":79,"type":22},202,[25],"The purpose of this research study is to evaluate whether telerehabilitation targeting arm movement, when added to usual care, improves arm function and reduces global disability after stroke, compared to usual care alone.\n\nPatients with arm weakness due to stroke that happened in the past 90-150 days will be randomized into one of two groups: \\[1\\] TR and usual care; \\[2\\] usual care only (no TR), but people in the usual care group will be offered TR once the study is done. TR consists of 70 minutes\u002Fday of activities targeting arm function, 6 days a week for 6 weeks.",[83],"Stroke",[85,86,87],"stroke","rehabilitation","telehealth","2026-08-17",{"date":61,"type":38},{"date":91,"type":38},"2025-08-22",{"date":93,"type":22},"2030-06",{"name":44,"class":45},27,{"id":97,"slug":98,"hasResults":12,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":12,"sex":18,"minAge":76,"maxAge":104,"enrollmentInfo":105,"targetDuration":4,"studyType":23,"phases":107,"briefSummary":108,"conditions":109,"keywords":112,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":123},"100562907","trial-of-device-that-is-not-approved-or-cleared-by-the-us-fda-100562907","NCT06609265","Extracorporeal Shockwave Therapy (ESWT) for the Management of Stress Fractures and High-grade Bone Stress Injuries (BSIs)","A Randomized, Double-blind, Dose-escalation, Sham-controlled Trial to Evaluate the Safety and Feasibility of Extracorporeal Shockwave Therapy (ESWT) for the Management of Stress Fractures and High-grade Bone Stress Injuries (BSIs)","ESWT\u002FBSI","Inclusion Criteria:\n\n* Male or female 18 - 50 years of age who engage in greater than or equal to 2.5 hours a week of physical activity (in any sport, with the primary aim to maintain health and fitness), at screening.\n* Documentation of pelvic or lower extremity BSI diagnosis as evidenced by one or more clinical features consistent with the high-grade BSI by MRI grading (stress reactions of MRI grade 3 or stress fracture, grade 4 by Fredericson MRI Grading) with specific stress injury sites to be included: pelvis (including pubic ramus and sacrum), compression-sided femoral neck with fracture line less than 50% diameter if grade 4, femoral shaft, posteromedial tibia, calcaneus, metatarsal (2nd-4th, excluding proximal 2nd), and fibula.\n* Written informed consent obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study.\n* If on NSAIDs, willing to refrain from use during the study.\n* If female of child-bearing potential, both of the following must be met at screening:\n* Practices one of the following methods of contraception and continues through the duration of the study: abstinence, hormonal contraceptives, IUD, spermicide and barrier or implantable device, and\n* Has a negative urine qualitative beta-HCG pregnancy test.\n* If female and post-menopausal one of the following must be met at screening:\n* Has had a complete hysterectomy, bilateral salpingo-oophorectomy or tubal ligation or otherwise be incapable of pregnancy, or\n* Is postmenopausal for at least one year.\n\nExclusion Criteria:\n\n* Pregnant, breastfeeding, plans to become pregnant during the study, or unwilling to practice birth control during participation in the study.\n* Unsuitable candidate for the study, based on the opinion of the investigator (e.g. cognitive impairment), such that participation might create undue risk to the subject or interfere with the subject\\'s ability to comply with the protocol requirements or complete the study.\n* Subjects who, at entry, are known to have alternative treatment (e.g. surgery) planned within the next 8 weeks.\n* History of severe osteoporosis (prior DXA scan with Z-score of -3.0 or T-score less than or equal to -2.5 and prior fracture history) or other underlying bone disease\u002Fdisorder.\n* Chronic rheumatologic condition and\u002For history of chronic oral steroid use.\n* Type II diabetes, other chronic underlying disease.\n* Morbid obesity (Body Mass Index greater than or equal to 35) at screening.\n* Has clinically significant renal disease defined as having an estimated creatinine clearance of greater than or equal to 40mL\u002Fmin at screening.\n* History of osteomyelitis in the injured area on which the treatment is to be administered at screening.\n* Has a current history of substance abuse (current is defined as within 120 days of screening).\n* Has evidence of a prior fracture or BSI within the last 6 months in the same area as the current injury.\n* Has active cellulitis or wound either at the injury site, or in the surrounding area at screening.\n* Has an injury requiring surgical intervention at screening.\n* Current\u002Factive DSM-V eating disorder diagnosis.\n* History of vascular insufficiency.\n* History of neurologic insufficiency.\n* History of coagulopathy, including previous deep vein thrombosis within six months of Visit 1; and\u002For therapy with anticoagulation medication (e.g. warfarin).\n* Radiation treatment within 120 days of Visit 1.\n* Presence of malignant disease with or without metastases.\n* Has a life expectancy of less than or equal to 2 years.\n* History of sickle cell anemia.\n* Has a known immunodeficiency disorder to include, but not be limited to: AIDS, HIV, etc.\n* Has participated in another investigation within 30 days of Visit 1.\n* Has previously received extracorporeal shockwave therapy (ESWT) with a SANUWAVE device.","50 Years",{"count":106,"type":22},140,[25],"The goal of this clinical trial is to evaluate the clinical safety and efficacy of Extracorporeal Shockwave Therapy (ESWT) for the management of high-grade Bone Stress Injuries (BSIs) in collegiate and recreational athletes compared to a control group receiving standard of care with sham ESWT.\n\nThe primary and secondary endpoints of the study are to evaluate the safety and feasibility of extracorporeal shockwave therapy for the treatment of pelvic and lower limb extremity fracture or BSI.\n\nResearchers will compare the ESWT group to the sham ESWT group to see if ESWT results in better safety and efficacy outcomes for treating high-grade BSIs.\n\nParticipants will:\n\n* Undergo a screening period to determine eligibility.\n* Receive up to 4 treatment sessions of ESWT, with the frequency of sessions being approximately every 5 days (within a range of every 3-10 days).\n* Be monitored for up to 6 months for research follow-up, with further questionnaires and check-ins during the standard of care follow-up period until they are able to return to sport activity level.",[110,111],"Bones Stress Injury","Bone Stress Fracture",[102,113,114],"Shockwave","stress fractures","2026-08-12",{"date":117,"type":38},"2026-08-13",{"date":119,"type":38},"2025-05-01",{"date":121,"type":22},"2027-11-01",{"name":44,"class":45},4,{"id":125,"slug":126,"hasResults":12,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":17,"sex":18,"minAge":76,"maxAge":131,"enrollmentInfo":132,"targetDuration":4,"studyType":23,"phases":134,"briefSummary":135,"conditions":136,"keywords":138,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":46},"100567494","irritable-bowel-syndrome-and-control-volunteers-diet-challenge-100567494","NCT06668922","Irritable Bowel Syndrome and Control Volunteers: Diet Challenge","Fecal Bile Acids, Fecal Short Chain Fatty Acids and the Intestinal Microbiota in Patients With Irritable Bowel Syndrome (IBS) and Control Volunteers: Diet Challenge","Inclusion Criteria:\n\n* Age 18-75\n* Individuals with irritable bowel syndrome (IBS)\n* Healthy volunteers (healthy controls) with no prior history of gastrointestinal (GI) disease or symptoms\n* No dietary restrictions other than vegetarian\n\nExclusion Criteria:\n\n* Inflammatory bowel disease, celiac disease, or certain types of abdominal cancer, as well as those with thyroid or liver issues\n* Abdominal surgery or abdominal radiation within 6 months of study participation, with an exception for C-section or gallbladder removal\n* Use of any prescription, over the counter, or herbal medications known to affect gastrointestinal function or study interpretation, such as opioids, inflammatory drugs or certain antidepressants, within 6 months prior to study participation for healthy volunteers, or within 2 days of study participation for participants with IBS.\n* An exception will be permitted for limited use of stable low doses of antidepressants for individuals who have been taking them for a period greater than one month.\n* Rescue medication such as Bisacodyl (dulcolax) to relieve severe constipation and allow for stool collection will be permitted when needed.\n* Use of Ozempic and Ozempic-type medications\n* Pregnant or breastfeeding women\n* Antibiotic use within 3 months of study participation\n* Use of prebiotics or probiotics within the 2 weeks before the study initiation\n* Regular tobacco use within the past 6 months","75 Years",{"count":133,"type":22},72,[25],"The study will investigate the relationship between fecal bile acids, short-chain fatty acids (SCFAs), and the gut microbiota in irritable bowel syndrome (IBS). The central hypothesis of this study is that specific shifts in the GI microbiome composition correlate with altered colonic SCFAs and BAs and contribute to IBS symptoms. Primary aims include: (a) identifying GI microbiome signatures in IBS subtypes (IBS-C and IBS-D) and matched controls, and test if microbiome signatures in these groups correlate with fecal SCFAs and bacterial fermentation of an indigestible carbohydrate (inulin) after a dietary challenge (fecal inulin), and (b) determining if GI microbiome signatures in IBS subtypes and controls correlate with fecal BAs or markers of SCFA production (fecal SCFAs or inulin) and test if BAs correlate with fecal SCFAs or inulin.\n\nThe target population is adults ages 18-65 years meeting Rome IV criteria for IBS (both diarrhea- and constipation-predominant, IBS-D and IBS-C) and asymptomatic controls. Primary outcomes will be fecal bile acid excretion and profile, short-chain fatty acid excretion and profile, colonic transit, and fecal microbiota. Secondary outcomes will be stool characteristics based on responses to validated bowel diaries. Stool samples will be collected from participants during the last 2 days of a 4-day 100 g fat diet and split into 3 samples for fecal microbiota, SCFA, and bile acid analysis.",[137],"Irritable Bowel Syndrome (IBS)",[139,140,141,142,143,144,145],"irritable bowel syndrome","IBS","short-chain fatty acids","SCFAs","bile acids","fecal inulin","microbiota","2026-08-11",{"date":115,"type":38},{"date":149,"type":38},"2024-11-28",{"date":151,"type":22},"2030-12-31",{"name":44,"class":45},{"id":154,"slug":155,"hasResults":12,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":17,"sex":18,"minAge":76,"maxAge":160,"enrollmentInfo":161,"targetDuration":4,"studyType":23,"phases":163,"briefSummary":164,"conditions":165,"keywords":167,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":46},"100606569","inter-brain-synchrony-in-schizophrenia-100606569","NCT07177261","Inter-Brain Synchrony in Schizophrenia","Inter-Brain Synchrony as a Neural Mechanism of Social Connection in Schizophrenia","Inclusion Criteria:\n\n* sufficient English fluency to comprehend procedures\n* clinical group will include individuals with a DSM-5 diagnosis of schizophrenia who are clinically stable (outpatients, with no hospitalizations 3 months prior to enrollment and no medication changes 1 month prior to enrollment)\n* members of the community without a psychotic disorder, schizophrenia-spectrum disorder, or current major mood disorder, nor history of a first-degree relative with a psychotic disorder.\n\nExclusion Criteria:\n\n* evidence of IQ \\\u003C 70 or developmental disability\n* history of significant neurological disease, serious head injury, or significant current substance use (moderate or severe substance use disorder in the last 3 months, positive urine toxicology screen on the day of assessment, or sedatives\u002Fanxiolytics taken within 12 hours of the assessment)","65 Years",{"count":162,"type":22},100,[25],"The goal of this clinical trial is to investigate for the first time in people with schizophrenia a neural mechanism that is thought to facilitate the formation of social connections - inter-brain synchrony - in order to improve scientific understanding of the neural mechanisms of social dysfunction in the disorder, and to provide a basis for the development of new and better treatments to improve social functioning and connectedness in the illness. The main questions it aims to answer are:\n\n1. Investigate inter-brain synchrony as a neural mechanism of social connection in schizophrenia\n2. Manipulate social closeness and test for effects on inter-brain synchrony across groups\n\nThe investigators will compare results from people with schizophrenia to a healthy comparison group (controls) who do not have psychotic disorders to see if inter-brain synchrony is greater in controls. Investigators will also compare measures of inter-brain synchrony before and after the social closeness manipulation to see if inter-brain synchrony changes with increasing closeness.\n\nParticipants will:\n\n* Have a clinicial diagnostic interview and be assessed for clinical symptoms\n* Have an EEG recorded while interacting with another person. Participants will first work with the other person to draw a figure, and then tap fingers together. Participants will then either undergo the experimental manipulation to increase social closeness (called, \"fast friends\") or undergo the control condition that does not increase social closeness (called \"small talk\"). Participants will then repeat the drawing and finger tapping assessment.\n* After completing the experimental or control condition, participants will then repeat the procedure with the other condition that was not yet done.\n* Be interviewed on the number and quality of social interactions.",[166],"Schizophrenia Disorder",[168,169,170,171,172],"schizophrenia","EEG","interbrain synchrony","hyperscanning","social connections","2026-08-07",{"date":146,"type":38},{"date":176,"type":38},"2025-11-11",{"date":178,"type":22},"2027-11-30",{"name":44,"class":45},{"id":181,"slug":182,"hasResults":12,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":4,"eligibilityCriteria":186,"healthyVolunteers":12,"sex":18,"minAge":76,"maxAge":131,"enrollmentInfo":187,"targetDuration":4,"studyType":23,"phases":189,"briefSummary":190,"conditions":191,"keywords":194,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":197,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":46},"100405247","pain-and-major-depressive-disorder-100405247","NCT04556890","Pain and Major Depressive Disorder","Multi-target Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment for Major Depressive Disorder (MDD) and Comorbid Pain","Inclusion Criteria:\n\n* All Subjects must be between 18-75 years of age\n* Language: Participants must speak English fluently, as demonstrated by verbal skills sufficient to answer questions at a level that assures adequate understanding of the study\n* Must have confirmed diagnosis of moderate Major Depressive Disorder (single or recurrent episode), minimum score of 17 on the 17-item Hamilton Rating Scale for Depression (HAM-D17). No minimal MDD duration necessary for study participation\n* Failure to respond to a minimum of 2 trials of antidepressant medication\n* Failure to respond from at least two different agent classes\n* Accompanied by at least two evidence-based augmentation therapies (Benzodiazepines do not count)\n* Must have a trial of psychotherapy known to be effective in the treatment of MDD of an adequate frequency and duration\\*\n* Must have a confirmed FM or ME\u002FCFS diagnoses and moderate pain complaints, minimum score of 15 on the McGill Pain Questionnaire.\n* Pain chronicity for at least 3 months prior to study enrollment.\n* Subjects are willing and able to adhere to the treatment schedule and required study visits.\n\nExclusion Criteria:\n\n* Are mentally or legally incapacitated, unable to give informed consent.\n* Are pregnant.\n* Have an active suicidal intent or plan.\n* Have had prior Transcranial Magnetic Stimulation treatment.\n* Have an infection or poor skin condition over the scalp where the device will be positioned.\n* Have increased risk of seizure because of family history, stroke, or currently use medications that lead to increased risk for seizure.\n* Psychotic depression or other acute or chronic psychotic symptoms or disorders (such as schizophrenia, schizophreniform or schizoaffective disorder) in the current depressive episode.\n* Neurological conditions that include epilepsy, cerebrovascular disease, dementia, increased intracranial pressure, having a history of repetitive or severe head trauma, or with primary or secondary tumors in the central nervous system.\n* Presence of an implanted metallic and magnetic-sensitive medical device present in the body scan, including but not limited to a cochlear implant, infusion pump, implanted cardioverter defibrillator, pacemaker, vagus nerve stimulator, aneurysm clip, metal prosthesis, or metal aneurysm clips or coils, staples, or stents. (Note: Dental amalgam fillings are not affected by the magnetic field and are acceptable for use with transcranial magnetic stimulation and MRI)",{"count":188,"type":22},54,[25],"This study will examine the effects of brain stimulation on pain symptoms associated with Major depressive disorder. This study will enroll 54 Subjects. Study subjects will be asked to complete surveys about their mood and well-being, 2 blood draws, 2 MRIs, 3 electroencephalograms, and receive 30 treatments of blinded transcranial magnetic stimulation. There is no control group as all subjects will receive some form of active treatment. Subjects are required to participate in 30-33 study visits and volunteer 40 hours of their time. Compensation for this study is $150 for completing all study activities.",[192,193],"Major Depressive Disorder","Chronic Pain",[195,196,193],"TMS","MDD",{"date":146,"type":38},{"date":199,"type":38},"2023-03-01",{"date":201,"type":22},"2027-12-31",{"name":44,"class":45},{"id":204,"slug":205,"hasResults":12,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":209,"eligibilityCriteria":210,"healthyVolunteers":12,"sex":18,"minAge":76,"maxAge":160,"enrollmentInfo":211,"targetDuration":4,"studyType":23,"phases":213,"briefSummary":214,"conditions":215,"keywords":219,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":228,"locationsCount":229},"100608126","treatment-of-borderline-personality-disorder-with-rtms-100608126","NCT07197502","Treatment of Borderline Personality Disorder With rTMS","CLINICAL TRIAL: Treatment of Borderline Personality Disorder by Targeting Ventrolateral Prefrontal-amygdala Circuit With Network-based Neuronavigated Transcranial Magnetic Stimulation","ClinicalBPD","* Age of 18-65\n* DSM-5 Diagnosis of BPD based upon a psychiatric evaluation and ZAN-BPD\n* Fluent English speaker\n* Signed informed consent",{"count":212,"type":22},30,[25],"This project studies the effectiveness of brain stimulation on borderline personality disorder (BPD) symptoms. This study is blinded, randomized and will enroll up to 30 participants.\n\nParticipant will be consented for the study remotely via a secure internet platform called Zoom.\n\nParticipants will undergo up to 2 MRI scans, 2 brain wave recording sessions and up to 30 brain stimulation treatments, and complete symptom assessments and cognitive behavioral tasks on a computer. Participation requires minimum of 17 in person visits over the course of 2.5 months.\n\nParticipants are randomly assigned active or sham brain stimulation. Participants who received sham brain stimulation have the option to receive additional 15 active brain stimulation session.",[216,217,218],"Borderline Personality Disorder","Borderline Personality","BPD - Borderline Personality Disorder",[220,221,195,216],"BPD","rTMS","2026-08-05",{"date":224,"type":38},"2026-08-10",{"date":226,"type":38},"2025-03-01",{"date":201,"type":22},{"name":44,"class":45},2,{"id":231,"slug":232,"hasResults":12,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":4,"eligibilityCriteria":236,"healthyVolunteers":12,"sex":18,"minAge":237,"maxAge":160,"enrollmentInfo":238,"targetDuration":4,"studyType":23,"phases":240,"briefSummary":242,"conditions":243,"keywords":246,"overallStatus":252,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":257,"leadSponsor":259,"locationsCount":4},"100642885","phase-2-thcv-treatment-for-smokers-100642885","NCT07636356","THCV Treatment for Smokers","Development of Tetrahydrocannabivarin as a Treatment for Smokers","Inclusion Criteria:\n\n1. Be between the ages of 21 and 65;\n2. Smoke 10 or more combustible cigarettes per day;\n3. Have fewer than 3 months of smoking abstinence in the past year;\n4. Has self-reported ≥10 lifetime uses of cannabis products;\n5. Have self-reported recent (past 3-month) use of cannabis products;\n6. Agree to abstain from all other cannabinoid use during the study;\n7. Agree to abstain from all other medication use during the study, other than methods of birth control as listed in inclusion criteria for female participants;\n8. Agree to one of the following methods of birth control (if female), unless she or partner are surgically sterile: oral contraceptives, Contraceptive sponge, patch, double barrier, intrauterine contraceptive device, etonogestrel implant, medroxyprogesterone acetate contraceptive injection, hormonal vaginal contraceptive ring, complete abstinence from sexual intercourse.\n\nExclusion Criteria:\n\n1. Have current (last 12 months) DSM-5 diagnosis of substance use disorder for any psychoactive substances other than nicotine;\n2. Have a lifetime DSM-5 diagnosis of schizophrenia, bipolar disorder, or any other psychotic disorder;\n3. Have a score of 3 or greater on the Columbia Suicide Severity Rating Scale (C-SSRS) at screening or anytime during study participation;\n4. Have a positive urine screen for any substances, including cannabis\n5. Have a breathalyzer reading above 0.000 g\u002Fdl;\n6. Be pregnant, nursing, or planning to become pregnant while taking part in the study;\n7. Have a medical condition that may interfere with safe study participation;\n8. Have clinically significant abnormalities on the EKG;\n9. Have evidence of renal impairment, defined by an eGFR value of \\\u003C90 ml\u002Fmin;\n10. Have evidence of hepatic impairment, defined by a score of ≥5 points on the Child-Pugh assessment of liver function;\n11. Exceed Grade 2 laboratory or vital sign abnormalities, based on FDA Guidance Document \"Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials\";\n12. Have past month use of cannabis or cannabis products;\n13. Have past month use of electronic nicotine delivery system (ENDS);\n14. Have use of any medications (other than methods of birth control as listed in inclusion criteria for female participants) within 14 days or 5 half-lives (whichever is longer) prior to study drug administration, and throughout the study, including medication for smoking cessation, any prescription, OTC, dietary supplements, herbal products, or vitamins;\n15. Have any other circumstances that, in the opinion of the investigators, would not be a good fit for study participation.","21 Years",{"count":239,"type":22},32,[241],"PHASE2","This study will randomize 32 non-treatment-seeking individuals who smoke cigarettes daily into a randomized, crossover, double-blind, placebo-controlled study testing the safety, tolerability, and initial efficacy of Δ9-tetrahydrocannabivarin (Δ9-THCV).",[244,245],"Tobacco Use Disorder","Smoking Cessation",[247,248,249,250,251],"smoking cessation","tobacco use disorder","cigarette smoking","THCV","Tetrahydrocannabivarin","NOT_YET_RECRUITING","2026-08-03",{"date":255,"type":38},"2026-08-04",{"date":66,"type":22},{"date":258,"type":22},"2028-05-31",{"name":44,"class":45},{"id":261,"slug":262,"hasResults":12,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":4,"eligibilityCriteria":266,"healthyVolunteers":17,"sex":267,"minAge":76,"maxAge":4,"enrollmentInfo":268,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":270,"conditions":271,"keywords":273,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":46},"100606891","nirs-for-the-diagnosis-of-myofascial-pelvic-pain-100606891","NCT07181447","NIRS for the Diagnosis of Myofascial Pelvic Pain","Quantitative Assessment of Pelvic Floor Muscle Fitness in Myofascial Pelvic Pain","Inclusion Criteria:\n\n* Women between 18 and 100 years of age\n* Pelvic pain for more than 6 months duration\n* Report an average daily pain intensity score of at least 4 (on a 0 to 10 scale)\n* Palpable trigger\u002Ftender points in internal pelvic floor muscles on standardized myofascial pelvic floor exam\n* Willing to refrain from new clinical treatments that may affect pain during the study period\n\nExclusion Criteria:\n\n* Inability to participate in clinic visits\n* Prior invasive pelvic procedures for pain (e.g., prior pelvic surgery, sacral neuromodulation, intradetrusor Botox®)\n* Active UTI or vaginal infection\n* Pregnancy, childbirth during the previous 12 months, currently planning pregnancy\n* Illicit Drug addiction\u002Fregular use of controlled substances\n* Malignancy or other serious medical condition (e.g., poorly controlled diabetes \\[HgA1c \\> 8\\], neurologic or rheumatic disease)\n* Diagnosed with an alternate cause of pelvic pain (e.g., interstitial cystitis, vestibulodynia, vulvar dermatoses dysmenorrhea)\n* Urinary retention\n* Greater than stage 3 pelvic organ prolapse\n* Indwelling vaginal devices (e.g., pessary, contraceptive ring)\n* Inability to sign an informed consent, fill out questionnaires, or complete study interviews","FEMALE",{"count":269,"type":22},110,"Myofascial Pelvic Pain (MPP) is an often-misdiagnosed condition affecting up to 26% of women during their lives and imposing enormous costs on national health care systems. It frequently involves comorbidities such as bladder, bowel, and sexual dysfunction. There are no quantitative measures that adequately guide the physician and accurate diagnosis typically requires an internal examination by a tertiary specialist.\n\nThis study will develop and test an instrument to establish a normal range for near infrared spectroscopy (NIRS) optical changes associate with pelvic floor exercise in adult women based on the test-to test (intra-day) reliability of oxygen kinetics related to contraction of the pelvic floor muscle.\n\nWe will establish the relationship between the quantitative NIRS data, the condition of Myofascial pelvic musculature and the symptomatology of MPP and related comorbidities. We will also evaluate prospectively the effectiveness of these data in predicting effective treatment modalities. Finally, we will optimize a training regime for non-specialists to allow this technique to be used in a variety of settings.\n\nThe development of this device and validation of its relevance to diagnosis and treatment of MPP will provide effective care sooner and at a lower cost than current procedures. It will also reduce inequities in the availability of care to underserved populations by providing an inexpensive, reliable and easily available method for a variety of providers to address MPP.",[272],"Myofascial Pelvic Pain",[274],"pelvic pain","2026-08-02",{"date":255,"type":38},{"date":278,"type":38},"2025-01-23",{"date":280,"type":22},"2026-09-01",{"name":44,"class":45},{"id":283,"slug":284,"hasResults":12,"nctId":285,"briefTitle":286,"officialTitle":286,"acronym":4,"eligibilityCriteria":287,"healthyVolunteers":12,"sex":18,"minAge":76,"maxAge":288,"enrollmentInfo":289,"targetDuration":4,"studyType":23,"phases":290,"briefSummary":291,"conditions":292,"keywords":296,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":306,"completionDateStruct":308,"leadSponsor":309,"locationsCount":46},"100507653","improving-cognition-through-telehealth-aerobic-exercise-and-cognitive-training-after-a-first-schizophrenia-episode-100507653","NCT05890183","Improving Cognition Through Telehealth Aerobic Exercise and Cognitive Training After a First Schizophrenia Episode","Inclusion Criteria:\n\n1. a first episode of a psychotic illness that began within the past three years;\n2. a diagnosis by DSM-5 of schizophrenia, schizoaffective disorder, or schizophreniform disorder;\n3. age 18 to 45 years of age;\n4. sufficient acculturation and fluency in the English language to avoid invalidating research measures; and\n5. residence likely to be within commuting distance of the UCLA Aftercare Research Program.\n\nExclusion Criteria:\n\n1. premorbid IQ less than 70;\n2. evidence of a known neurological disorder (e.g., epilepsy) or significant head injury;\n3. evidence of moderate or severe substance use disorder within the six months prior to the first episode or evidence of a substance-induced psychosis.","45 Years",{"count":162,"type":22},[25],"The participants in the study will receive psychiatric treatment at the UCLA Aftercare Research Program. All participants in this 12-month RCT will receive cognitive training. Half of the patients will also be randomly assigned to the aerobic exercise and strength training condition, and the other half will be randomly assigned to the Healthy Living Group condition. The primary outcome measures are improvement in cognition and level of engagement in the in-group and at-home exercise sessions. Increases in the level of the patient's serum brain-derived neurotropic factor (specifically Mature BDNF) which causes greater brain neuroplasticity and is indicator of engagement in aerobic exercise, will be measured early in the treatment phase in order to confirm engagement of this target. In order to demonstrate the feasibility and portability of this intervention outside of academic research programs, the interventions will be provided via videoconferencing. The proposed study will incorporate additional methods to maximize participation in the exercise condition, including the use of the Moderated Online Social Therapy (MOST) platform to enhance motivation for treatment based on Self-Determination Theory principles, and a \"bridging\" group to help the participants generalize gains to everyday functioning. In addition, the exercise group participants will receive personally tailored text reminders to exercise.",[293,294,295],"Schizophrenia","Schizophreniform Disorder","Schizoaffective Disorder",[297,298,299,300,301,302,303],"First-Episode Schizophrenia","Cognitive Remediation","Physical Exercise","Brain Derived Neurotrophic Factor","Telehealth Intervention","Moderated Online Social Therapy (MOST)","Motivational Text Messaging Program (Chorus)","2026-08-01",{"date":255,"type":38},{"date":307,"type":38},"2023-05-23",{"date":258,"type":22},{"name":44,"class":45},{"id":311,"slug":312,"hasResults":12,"nctId":313,"briefTitle":314,"officialTitle":315,"acronym":316,"eligibilityCriteria":317,"healthyVolunteers":12,"sex":18,"minAge":54,"maxAge":77,"enrollmentInfo":318,"targetDuration":4,"studyType":23,"phases":320,"briefSummary":322,"conditions":323,"keywords":326,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":328,"lastUpdatePostDateStruct":329,"startDateStruct":330,"completionDateStruct":332,"leadSponsor":334,"locationsCount":46},"100541218","early-phase-1-thiamine-intervention-and-coronary-artery-bypass-grafting-100541218","NCT06326996","Thiamine Intervention and Coronary Artery Bypass Grafting","Thiamine Intervention and Cognition in Older Adults Undergoing Coronary Artery Bypass Grafting - A Randomized Clinical Trial.","B1&CABG","Inclusion Criteria:\n\n* Patients with Coronary Heart Disease (CHD) scheduled for Bypass Grafting (CABG)\n* Thiamine deficiency before CABG\n* European System for Cardiac Operative Risk Evaluation II (EuroSCORE II) \\>1.5%\n* Off-pump surgery\n\nExclusion Criteria:\n\n* Dementia at baseline \\[Montreal Cognitive Assessment (MoCA) \\\u003C21 within 5 days before CABG\\]\n* Current in-take of thiamine\n* Known thiamine allergy\n* Uncontrolled blood glucose levels\n* Unable to give consent due to illness\n* History of hyperlactatemia\n* Recent (within several years and\u002For up to the judgment of the PI\u002Fco-PIs) cerebral incidents (seizure or head trauma resulting in loss of consciousness and\u002For concussion)\n* Stroke\n* Diagnosed psychiatric diseases (clinical depression, schizophrenia, manic-depression)\n* Patients with history of alcohol or substance abuse\n* Acute or chronic infections (tuberculosis, hepatitis, or encephalopathy)\n* Diagnosed neuro-degenerative diseases (Alzheimer's or Parkinson's disease)\n* Chronic immunodeficiency (including HIV)\n* Congenital brain deficits will also be excluded",{"count":319,"type":22},52,[321],"EARLY_PHASE1","The purpose of this study is to gain a better understanding of the association between brain changes and cognitive deficits in coronary heart disease (CHD) patients undergoing coronary artery bypass grafting (CABG) and whether a low-cost thiamine intervention can be used to reduce post-CABG cognitive issues in CHD subjects.",[324,325],"Coronary Heart Disease","Coronary Artery Bypass Grafting",[327],"thiamine intervention","2026-07-31",{"date":253,"type":38},{"date":331,"type":38},"2024-10-10",{"date":333,"type":22},"2026-09-30",{"name":44,"class":45},{"id":336,"slug":337,"hasResults":12,"nctId":338,"briefTitle":339,"officialTitle":340,"acronym":4,"eligibilityCriteria":341,"healthyVolunteers":12,"sex":18,"minAge":76,"maxAge":4,"enrollmentInfo":342,"targetDuration":4,"studyType":23,"phases":343,"briefSummary":345,"conditions":346,"keywords":348,"overallStatus":252,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":355,"startDateStruct":356,"completionDateStruct":358,"leadSponsor":360,"locationsCount":4},"100620249","phase-4-suzetrigine-versus-usual-care-opioids-for-postop-pain-in-sports-100620249","NCT07355166","Suzetrigine Versus Usual-care Opioids for Postop Pain in Sports","Suzetrigine Versus Usual-care Opioids for Postoperative Pain After Common Ambulatory Orthopaedic Sports Procedures - A Randomized Control Trial","Inclusion Criteria:\n\n* Patients undergoing reconstruction of primary ACL tear\n\nExclusion Criteria:\n\n* Concurrent ligamentous injuries requiring surgical intervention\n* Full thickness cartilage injury requiring discrete surgical intervention\n* Chronic opioid use\n* Significant hepatic disease (Child\u002FPugh C)\n* Women who are pregnant or breastfeeding\n* Women of childbearing age using hormonal contraceptives containing progestins other than levonorgestrel and norethindrone\n* Allergies or intolerance to any study medications\n* Inability to complete ePROs (due to literacy or infirmity)",{"count":106,"type":22},[344],"PHASE4","The goal of this clinical trial is to learn if a Suzetrigine-based multimodal pain regimen can reduce the volume of opioid consumption while maintaining non-inferior pain control compared to an opioid-based multimodal pain regimen after common ambulatory orthopaedic sports procedures. The main questions it aims to answer are:\n\n1. Does including Suzetrigine in the multimodal pain regimen lower the volume of opioids consumed by participants while maintaining non-inferior pain control?\n2. How does the side-effect profile of a Suzetrigine-based multimodal postop pain regimen compare to that of an opioid-based multimodal postoperative pain regimen?\n\nEligible participants will be assigned to receive one of the postop pain regimens and report their opioid use, their pain level, and the side effects they faced every day for 7 days.",[347],"Postoperative Pain Management",[349,350,351,352,353,347],"Suzetrigine","Journavx","Opioid Use","ACL Reconstruction","Rotator Cuff Repair","2026-07-29",{"date":328,"type":38},{"date":357,"type":22},"2026-09",{"date":359,"type":22},"2027-03",{"name":44,"class":45},{"id":362,"slug":363,"hasResults":12,"nctId":364,"briefTitle":365,"officialTitle":366,"acronym":4,"eligibilityCriteria":367,"healthyVolunteers":17,"sex":267,"minAge":4,"maxAge":4,"enrollmentInfo":368,"targetDuration":4,"studyType":23,"phases":370,"briefSummary":371,"conditions":372,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":375,"startDateStruct":376,"completionDateStruct":378,"leadSponsor":380,"locationsCount":46},"100593453","effect-of-watermelon-on-cardiometabolic-health-100593453","NCT07006636","Effect of Watermelon on Cardiometabolic Health","Effect of Watermelon Consumption on Cardiometabolic Health and Whole-Body Antioxidant Capacity","Inclusion Criteria:\n\n* Female\n* Generally healthy\n* Postmenopausal\n* BMI 25-40 kg\u002Fm2\n* Systolic blood pressure 120-139 mmHg and\u002For diastolic 80-89 mmHg\n* Fitzpatrick Skin type II-IV\n* Consume a typical Western diet (low in polyphenol\u002Flycopene-rich foods and fiber)\n* Willing to maintain habitual dietary and exercise patterns for the study duration\n* Willing to maintain normal skin care products and pattern for the duration of the study\n* Willing to come to Baseline Visit B and Week 4 study visits without any makeup and skin products on\n* Subjects must read and sign the Institutional Review Board-approved written informed consent prior to the initiation of any study specific procedures or enrollment. A subject will be excluded for any condition that might compromise the ability to give truly informed consent.\n\nExclusion Criteria:\n\n* Non-English speaker\n* Vegetarian\u002Fvegan\n* Known watermelon allergy\n* Skin-related prescription medication, supplements, or non-prescription cosmeceutical agents\n* Initiation of topical or oral prescription steroids and\u002For anti-inflammatory medications within 30 days prior to study enrollment\n* Excessive exposure to either natural or artificial sunlight. Exposure to sunlight will be evaluated using Fitzpatrick Skin Type test score. Individuals receiving scores higher than the upper cutoff of the proposed range for the specific skin type will be excluded\n* Screening laboratory values outside of the normal range that is considered clinically significant for study participation by the investigator\n* Documented chronic disease, including diabetes, renal or liver diseases, metabolic syndrome, active cancer, MI or stroke, history of gastric bypass or GI disease (e.g., Crohn's disease, IBD, diverticulosis, diverticulitis, etc.)\n* Taking medications or supplements known to affect metabolism or gut microbiota composition (antibiotics within the past 3 months, probiotics, fiber, etc.), unless willing to stop for the study duration\n* Taking exogenous hormones (e.g., hormone replacement therapy)\n* Recent weight fluctuations (\\>10% in the last 6 months)\n* Smoker or living with a smoker\n* Use of \\>20 g of alcohol per day\n* Unable or unwilling to comply with the study protocol (including unwillingness to avoid watermelon and other lycopene-rich foods for the whole duration of the study)\n* Unable to provide consent",{"count":369,"type":22},22,[25],"The purpose of this study is to determine whether consumption of 355 ml of watermelon juice will:\n\n1. improve cardiovascular and overall metabolic health markers like blood pressure, heart rate, stiffness\u002Fflexibility of arteries (blood vessels), blood sugar, cholesterol), and gut hormones\n2. contribute to the body's ability to protect itself from the potential cell damage caused by harmful chemical compounds (produced when skin is exposed to ultraviolet (UV) B light, for example). This will be evaluated by measuring how resistant skin is to the damage from UVB light exposure, as well as several markers of bodily stress blood and urine.\n\nThis will be determined immediately after consuming the juice (to evaluate the effects the juice has on health right away), as well as after 4 weeks of daily juice consumption (to evaluate the effects the juice has on health when consumed consistently over time).",[373,374],"Cardiometabolic Health Indicators","Whole-body Antioxidant Capacity",{"date":328,"type":38},{"date":377,"type":38},"2026-04-01",{"date":379,"type":22},"2027-09-01",{"name":44,"class":45},{"id":382,"slug":383,"hasResults":12,"nctId":384,"briefTitle":385,"officialTitle":385,"acronym":4,"eligibilityCriteria":386,"healthyVolunteers":12,"sex":387,"minAge":76,"maxAge":4,"enrollmentInfo":388,"targetDuration":4,"studyType":23,"phases":390,"briefSummary":391,"conditions":392,"keywords":4,"overallStatus":252,"whyStopped":4,"lastUpdateSubmitDate":394,"lastUpdatePostDateStruct":395,"startDateStruct":397,"completionDateStruct":398,"leadSponsor":400,"locationsCount":4},"100608393","people--place-impacts-on-substance-use-and-hiv-outcomes-in-los-angeles-100608393","NCT07200973","People & Place: Impacts on Substance Use and HIV Outcomes in Los Angeles","Inclusion Criteria:\n\n* Living with HIV\n* Assigned male sex at birth\n* Willing to return for follow-up study visits every six months as long as the study is ongoing and be available to return for all study visits, barring unforeseen circumstances\n* Willing and able to provide written informed consent to take part in the study\n* Willing and able to provide adequate information for locator purposes\n* Willing to undergo repeat HIV viral load testing at select study visits\n* Willing to undergo substance use testing at each study visit\n\nExclusion Criteria:\n\n* Born biologically female\n* Unwilling or unable to provide reliable contact information\n* Unwilling to provide urine or blood\n* Any other condition or prior therapy that, in the opinion of the research staff would preclude informed consent, make study participation unsafe, make the individual unsuitable for the study or unable to comply with the study requirements. Such conditions may include, but are not limited to, renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, neurological, or cerebral disease, among others","MALE",{"count":389,"type":22},250,[25],"This study will implement an adapted peer navigation intervention to improve linkage to and retention in HIV care for people living with HIV who experience substance use within Los Angeles County.",[393],"HIV","2026-07-24",{"date":396,"type":38},"2026-07-27",{"date":66,"type":22},{"date":399,"type":22},"2028-10",{"name":44,"class":45},{"id":402,"slug":403,"hasResults":12,"nctId":404,"briefTitle":405,"officialTitle":406,"acronym":4,"eligibilityCriteria":407,"healthyVolunteers":12,"sex":18,"minAge":160,"maxAge":4,"enrollmentInfo":408,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":410,"conditions":411,"keywords":413,"overallStatus":252,"whyStopped":4,"lastUpdateSubmitDate":416,"lastUpdatePostDateStruct":417,"startDateStruct":418,"completionDateStruct":419,"leadSponsor":421,"locationsCount":46},"100592587","refining-risk-prediction-models-for-older-adults-using-electronic-health-records-100592587","NCT06995365","Refining Risk Prediction Models for Older Adults Using Electronic Health Records","Patient-centered Precision Medicine Lab Result Communication for Older Adults - Validation and Refinement of an Existing Chronic Kidney Disease (CKD) Risk Model","Inclusion Criteria include, but are not limited to:\n\n* being over the age of 65; having at least 5 years of clinical follow up; and having a serum creatinine lab test conducted\n\nExclusion Criteria:\n\n* Patients younger than 65 years old\n* Patients with less than 5 years of clinical follow-up\n* Patients from health systems outside of the UC Health network.",{"count":409,"type":22},18000,"This study aims to improve how lab results are communicated to older adults by refining a predictive model that uses electronic health record (EHR) data. The model was originally developed to estimate the risk of chronic kidney disease (CKD) progression. Researchers will use existing health data to test and improve the accuracy of the model and explore how it might be adapted for use in other health conditions. The study does not involve direct interaction with patients and is conducted entirely using de-identified data in a secure environment.",[412],"Predictive Modeling",[414,415],"Lab Result Communication","Risk Stratification","2026-07-23",{"date":394,"type":38},{"date":357,"type":22},{"date":420,"type":22},"2028-03",{"name":44,"class":45},{"id":423,"slug":424,"hasResults":12,"nctId":425,"briefTitle":426,"officialTitle":427,"acronym":4,"eligibilityCriteria":428,"healthyVolunteers":17,"sex":18,"minAge":104,"maxAge":77,"enrollmentInfo":429,"targetDuration":4,"studyType":23,"phases":431,"briefSummary":432,"conditions":433,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":436,"lastUpdatePostDateStruct":437,"startDateStruct":438,"completionDateStruct":440,"leadSponsor":442,"locationsCount":46},"100584486","effect-of-daily-mixed-spice-consumption-on-memory-function-100584486","NCT06889961","Effect of Daily Mixed Spice Consumption on Memory Function","Effect of Daily Mixed Spice Consumption on Memory in Middle-Aged and Older Adults With Age-related Cognitive Decline: A Pilot Study","Inclusion Criteria:\n\n1. Participants are required to have clinical histories consistent with normal aging or mild cognitive impairment (MCI).\n2. Age 50 to 80 years.\n3. Adequate visual acuity and hearing to allow neuropsychological testing.\n4. Screening laboratory tests without significant abnormalities that might interfere with the study.\n\n   \\-\n\nExclusion Criteria:\n\n1. Diagnosis of probable Alzheimer's disease or any other dementia (e.g. vascular, Lewy body, frontotemporal)\n2. Evidence of other neurological or physical illness that can produce cognitive deterioration. Determination of dementia will be based on the clinical evaluation including assessment of functional abilities, and cognitive screening (using the Mini Mental State Examination\n3. Evidence of Parkinson's disease as determined by the motor examination (items 18-31) of the Unified Parkinson's Disease Rating Scale \\[38\\].\n4. Uncontrolled hypertension (systolic blood pressure (BP) \\> 170 or diastolic BP \\> 100).\n5. Consume spices regularly \\> 5g day\n6. Allergy or sensitivity to spices. Subjects will be excluded if there is a prior history of such sensitivity. Since these foods are commonly eaten and allergies are rare, subjects should be aware of this sensitivity prior to entering the study. To determine this, a positive history of spices ingestion without incident will be requested. In addition, any subject with a history of allergy or anaphylaxis of any kind will be excluded.\n7. Current diagnosis of any major psychiatric disorder according to the DSM-IV TR criteria (APA, 2000).\n8. Current diagnosis or alcoholism or substance addiction.\n9. Eating a high fiber\u002Fpolyphenol diet or taking any medication or dietary supplement which interfere with the absorption of polyphenols.\n10. Frequently using prebiotics, probiotics, yogurt, and\u002For any fiber supplements",{"count":430,"type":22},50,[25],"The aging process entails a multitude of structural and functional alterations within the brain, culminating in a gradual and progressive decline in cognitive function. Recent research has indicated that various spices may hold the key to enhancing brain health and combating the effects of aging on cognitive abilities. The hypothesis is that a mixture of spices, acknowledged for their reported memory protection potential, may yield a more potent beneficial effect on memory function than a single spice. The spice mixture will be used at culinary dose, and therefore side effects are anticipated. In this study, the effects of spice mixture will be evaluated, as well as their anti-oxidant, and anti-inflammatory properties. The proposed pilot study will include 50 adults (ages 50-80), exhibiting typical age-related mild cognitive decline, excluding dementia or major neurocognitive disorders. They will be randomized 1:1 assigned into a daily intake of either 4.00 g spice mixture capsules or 4.00 g maltodextrin capsules over 3 months, and explore the sustainable effect over 3 additional months. The changes in symptoms of cognition, fatigue, and mood symptoms of the spice group vs. placebo group will be compared. The outcome of the investigation of the effects of mixed spice consumption will provide important novel information on dietary recommendation of spice to preserve cognitive function in aging population.",[434,435],"Memory","Cognitive Function","2026-07-22",{"date":394,"type":38},{"date":439,"type":38},"2025-02-21",{"date":441,"type":22},"2027-02-21",{"name":44,"class":45},{"id":444,"slug":445,"hasResults":12,"nctId":446,"briefTitle":447,"officialTitle":448,"acronym":4,"eligibilityCriteria":449,"healthyVolunteers":12,"sex":18,"minAge":76,"maxAge":4,"enrollmentInfo":450,"targetDuration":4,"studyType":23,"phases":451,"briefSummary":452,"conditions":453,"keywords":455,"overallStatus":252,"whyStopped":4,"lastUpdateSubmitDate":436,"lastUpdatePostDateStruct":457,"startDateStruct":458,"completionDateStruct":460,"leadSponsor":462,"locationsCount":4},"100547735","mapping-patient-decision-making-in-thyroid-cancer-100547735","NCT06411834","Mapping Patient Decision-making in Thyroid Cancer","Mapping Patient Decision-making in Thyroid Cancer: Improving Decision Outcomes Through Ethnographic Decision Modeling","Inclusion Criteria:\n\n* Age \\>18\n* Newly diagnosed or suspected thyroid cancer\n\nExclusion Criteria:\n\n* Strong indication for total thyroidectomy\n* tumor size \\>4 cm\n* nodal or distant metastases\n* evidence of extrathyroidal extension\n* Non-English speaking",{"count":430,"type":22},[25],"The incidence of thyroid cancer has exploded in the past 5 decades, with a roughly three-fold increase since 1995. Fortunately, many new cases are small, early-stage thyroid cancers. The American Thyroid Association guidelines state that patients with papillary thyroid cancers less than 4 cm can choose either thyroid lobectomy or total thyroidectomy. However, it is unclear why patients will sometimes choose more aggressive treatments that carry additional operative risk when a less aggressive option is available. When investigators examined thyroid specialists' recommendations for thyroid cancer treatment, investigators found significant variation between physicians' risk estimates and their treatment recommendations. This illustrated that patients may receive inconsistent counseling regarding their diagnosis and treatment options from different providers. Worse yet, other studies have shown that patients often do not perceive a choice in their treatment. When patients undergo treatments that do not align with their own priorities and values, they may experience regret and low satisfaction. Decision aids have been shown to help patients feel more educated about their options but have not had an effect on their treatment choice, decision regret, or satisfaction.\n\nThe aim of this study is to use an ethnographic approach to map the patient decision-making process and develop a Decision Navigation Tool to improve decision outcomes for thyroid cancer patients. An ethnographic approach seeks to understand the social norms, culture, and context that influence these decisions. Investigators will do so in 3 phases: 1) elicit patient decision criteria in selecting initial treatment for thyroid cancer, 2) construction and validation of decision-tree model for initial treatment of thyroid cancer, and 3) pilot randomized controlled trial of a Decision Navigation Tool. To construct the decision model, investigators will recruit a diverse sample of patients with varying age, gender, race\u002Fethnicity, and operative and cancer outcomes. The Decision Navigation Tool will highlight patients' values and priorities and empower them to select a treatment aligned with their preferences. This study will provide important insights into the patient experience of decision-making in thyroid cancer and test the feasibility of a future multi-center large-scale clinical trial of a Decision Navigation Tool to improve decision outcomes.",[454],"Thyroid Cancer",[456],"decision-making",{"date":394,"type":38},{"date":459,"type":22},"2028-04",{"date":461,"type":22},"2029-06",{"name":44,"class":45},{"id":464,"slug":465,"hasResults":12,"nctId":466,"briefTitle":467,"officialTitle":467,"acronym":468,"eligibilityCriteria":469,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":470,"targetDuration":4,"studyType":23,"phases":472,"briefSummary":473,"conditions":474,"keywords":477,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":489,"lastUpdatePostDateStruct":490,"startDateStruct":491,"completionDateStruct":493,"leadSponsor":494,"locationsCount":46},"100647921","randomized-controlled-trial-of-the-stein-protocol-a-neuroplastic-pain-education-and-guided-breathing-intervention-during-awake-cataract-surgery-100647921","NCT07715591","Randomized Controlled Trial of the STEIN Protocol: A Neuroplastic Pain Education and Guided Breathing Intervention During Awake Cataract Surgery","SLin","Inclusion Criteria:\n\nAdults undergoing elective cataract surgery under topical anesthesia who are able to provide informed consent and complete study procedures.\n\nExclusion Criteria:\n\nInability to provide informed consent Inability to comply with study procedures Complex or combined cataract surgery General anesthesia Medical, neurologic, psychiatric, or respiratory conditions interfering with study participation Requirement for modified anesthetic protocols Inability to complete postoperative breathing exercises or follow-up assessments",{"count":471,"type":22},300,[25],"This randomized controlled trial evaluates whether a standardized perioperative neuroplastic intervention: the STEIN Protocol (Strategies and Techniques for Enhancing Integration and Neuroplasticity), consisting of pain neuroscience education, guided imagery, and paced breathing, reduces intraoperative analgesic and anxiolytic requirements.\n\nSecondary outcomes include patient-reported pain, anxiety, satisfaction, and postoperative recovery following cataract surgery.\n\nReduced intraoperative sedative and analgesic requirements may reflect improved patient comfort and autonomic regulation while minimizing medication-related adverse effects.",[475,476],"Cataract","Cataract (Post-operative Cataract Surgery Follow-up)",[478,479,480,481,482,483,484,485,486,487,488],"Cataract Surgery","Pain Neuroscience Education","Guided Imagery","Guided Breathing","Perioperative Care","Anxiety","Patient Satisfaction","Mind-Body Medicine","Meditation","Breathwrok","Pain","2026-07-21",{"date":416,"type":38},{"date":492,"type":38},"2026-06-10",{"date":280,"type":22},{"name":44,"class":45},{"id":496,"slug":497,"hasResults":12,"nctId":498,"briefTitle":499,"officialTitle":500,"acronym":4,"eligibilityCriteria":501,"healthyVolunteers":12,"sex":18,"minAge":76,"maxAge":4,"enrollmentInfo":502,"targetDuration":4,"studyType":23,"phases":503,"briefSummary":504,"conditions":505,"keywords":509,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":511,"lastUpdatePostDateStruct":512,"startDateStruct":514,"completionDateStruct":516,"leadSponsor":518,"locationsCount":46},"100647425","care-disengagement-prevention-in-plwh-in-indonesia-100647425","NCT07706634","Care Disengagement Prevention in PLWH in Indonesia","Care Disengagement Prevention in Treatment Naive Indonesians Living With HIV","Inclusion Criteria:\n\n* Living with HIV\n* Able to give informed consent\n* Able to attend study visits\n\nExclusion Criteria:\n\n* Condition that prevents full participation in the study such as neurological disease, major depression or cardiovascular disease\n* Unable to communicate",{"count":269,"type":22},[25],"This study is being done because the investigators want to learn about how stigma and culture in Indonesia affects how much contact people living with HIV have with the healthcare system and also how it might affect their health status.",[393,506,507,508],"Indonesia","Engagement in HIV Care","Stigma",[393,510],"Stigma reduction","2026-07-15",{"date":513,"type":38},"2026-07-17",{"date":515,"type":38},"2026-02-11",{"date":517,"type":22},"2028-01-31",{"name":44,"class":45},{"id":520,"slug":521,"hasResults":12,"nctId":522,"briefTitle":523,"officialTitle":523,"acronym":524,"eligibilityCriteria":525,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":237,"enrollmentInfo":526,"targetDuration":4,"studyType":23,"phases":528,"briefSummary":529,"conditions":530,"keywords":532,"overallStatus":252,"whyStopped":4,"lastUpdateSubmitDate":511,"lastUpdatePostDateStruct":535,"startDateStruct":537,"completionDateStruct":538,"leadSponsor":540,"locationsCount":46},"100647414","screening-for-social-determinants-of-health-in-routine-diabetes-care-100647414","NCT07706803","Screening For Social Determinants Of Health In Routine Diabetes Care","SDOH","Inclusion Criteria:\n\n* 1\\) patients who are 0-21 years old, diagnosed with T1D, and receive T1D care from the UCLA Pediatric Diabetes program at the Westwood clinic, and\u002For 2) parents\u002Flegal guardians of a child with T1D and whose child is 21 years old or under and receives T1D care from the UCLA Pediatric Diabetes program at the Westwood clinic.\n\nExclusion Criteria:\n\n* 1\\) patients who are over 21 years old and diagnosed with Type 2 Diabetes or prediabetes, and 2) parents\u002Flegal guardians of a child with type 2 diabetes or prediabetes and whose child is over 21 years old.",{"count":527,"type":22},150,[25],"Social determinants of health (SDOH) exert a powerful influence on the everyday management of type 1 diabetes (T1D) and short and long term outcomes of T1D. Experts agree that identifying and addressing negative social determinants of health (SDOH) may help accomplish numerous T1D care goals and promote health equity in treatment. However, fundamental research gaps in achieving these goals remain, including optimal screening and management processes for identification of negative social determinants of health (SDOH) , and how to develop robust partnerships with community-based organizations (CBOs) that address social determinants of health (SDOH) with high potential for sustainability and scalability. This project will generate new knowledge regarding how to implement a social work-led social determinants of health (SDOH) screening and referral program designed to aid families of youth with T1D who face several vulnerabilities, including food insecurity. The team will implement a single arm, pragmatic clinical trial with contemporaneous, non- randomized controls; whereby all families with a child enrolled in the California Children's Services (CCS) program (which provides specialized medical care for low-income families of youth with a qualifying chronic medical condition) will receive access to a novel social work-led social determinants of health (SDOH) screening and referral program.\n\nOutcomes will be compared against youth with T1D who are also seen in our Westwood Pediatric Endocrinology clinic but who are not enrolled in the CCS program and will not receive access to the social determinants of health (SDOH) intervention. The study team has established partnerships with several community-based organizations (CBOs) across Los Angeles County that provide social services, including food-related services, to receive referrals for CCS families who screen positive for having a social need. The study team will assess the feasibility and acceptability of this screening and referral protocol among families, CBOs, and providers (Aim 1) by measuring key implementation outcomes (comprehensive documentation of social determinants of health (SDOH) screening, result, and referral in the patients' medical record) and acceptability outcomes (self-reported satisfaction with the program by families and barriers and facilitators by CBOs and providers). The team will additionally estimate the effect of this intervention (Aim 2) by measuring changes (pre\u002Fpost intervention) in families reported social needs, diabetes-related quality of life, and in the child's glycemic control (measured by HbA1c). Results from this work can provide a roadmap for sustainable and scalable social determinants of health (SDOH) interventions with potential to improve outcomes for youth with T1D in an equity-informed manner.",[531],"Type 1 Diabetes",[533,534],"Type 1 diabetes","Pediatric",{"date":536,"type":38},"2026-07-16",{"date":357,"type":22},{"date":539,"type":22},"2028-09",{"name":44,"class":45},{"id":542,"slug":543,"hasResults":12,"nctId":544,"briefTitle":545,"officialTitle":545,"acronym":4,"eligibilityCriteria":546,"healthyVolunteers":17,"sex":18,"minAge":76,"maxAge":4,"enrollmentInfo":547,"targetDuration":4,"studyType":23,"phases":549,"briefSummary":550,"conditions":551,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":511,"lastUpdatePostDateStruct":553,"startDateStruct":554,"completionDateStruct":556,"leadSponsor":558,"locationsCount":46},"100513921","phase-2-fimepinostat-combination-hdac-and-pi3-kinase-inhibitor-tumor-directed-therapy-for-cushing-disease-100513921","NCT05971758","Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing Disease","Inclusion Criteria:\n\n* Male and female patients at least 18 years old\n* Patients with confirmed pituitary origin Cushing syndrome defined as 1, 2\\& 3 or 4 \\& 5 below:\n\n  1. Persistent hypercortisolism defined as a mean of 3 consecutive 24h UFC at baseline assessment ≥ 1.3x ULN\n  2. Normal or elevated plasma ACTH levels\n  3. Pituitary adenoma \\> 4mm visible on MRI or inferior petrosal sinus sampling (IPSS) central to peripheral ACTH gradient \\>2 at baseline and\u002For \\>2 after DDAVP stimulation.\n  4. Recurrent or persistent CD defined as pathologically confirmed previously resected pituitary ACTH-secreting tumor, and 24 hour UFC \\>ULN at least 4 weeks after pituitary surgery.\n  5. Patients on medical treatment for CD. Washout periods will be completed as below before screening: Inhibitors of steroidogenesis (metyrapone, ketoconazole, osilodristat,\n\n     * Levo-ketoconazole): 2 weeks\n     * SRLs (pasireotide): 2 weeks\n     * Progesterone receptor antagonist (mifepristone): 2 weeks\n     * Dopamine agonists (cabergoline): 4 weeks\n     * CYP3A4 strong inducers or inhibitors: varies between drugs; minimum 5-6 times the half-life of drug\n\nExclusion Criteria:\n\n* Patients with compromised visual fields, or evidence of visual changes within past 6 months\n* Patients with sellar tumor abutting or compressing the optic chiasm on MRI and normal visual fields\n* Patients with Cushing's syndrome not due to an ACTH-secreting pituitary tumor\n* Patients who have undergone major surgery including pituitary surgery within 1 month of screening or who have any major surgical procedures planned across the study period\n* Patients with serum potassium \\\u003C 3.5 mEq\u002FL unless stably controlled on potassium supplementation\n* Patients with poorly-controlled Diabetes mellitus evidenced by HbA1c levels \\>8\n* Patients with poorly controlled hypertension (i.e. blood pressure ≥ 160\u002F100 mm Hg)\n* Patients who have clinically significant cardiovascular impairment, as evidenced by the presence of bradycardia, ventricular tachycardia, history of myocardial infarction within past year, or any other cardiovascular impairment that may pose significant health risk in view of the investigator.\n* Patients with liver disease or history of liver disease such as cirrhosis, chronic active hepatitis B and C, or chronic persistent hepatitis, or patients with ALT or AST \\>1.5 x ULN, serum total bilirubin \\>ULN, serum albumin \\\u003C0.67 x LLN at screening\n* Patients with renal disease or history of renal disease with creatinine clearance of 30 cm3\u002Fmin or less and\u002For creatinine \\> 1.5 mg\u002Fdl at screening\n* Patients not biochemically euthyroid. Patients receiving thyroid-replacement therapy must be on a stable dose for at least 3 months.\n* Patients who are known to be positive for HIV, or any other condition that significantly compromises subject's immune system.\n* History of alcohol abuse or illicit substance use within past year.\n* Female patients who are pregnant or lactating or are of childbearing potential unless willing to practice acceptable method of birth control. Women participating in the trial must employ double barrier method through oral contraceptive or diaphragm with partner utilizing a condom. Abstinence is an acceptable form of birth control if routinely practiced. Male participants must utilize a condom with spermicidal cap\u002Fjelly and agree to not donate sperm for up to 3 months beyond main study period.\n* Patients who have participated in any clinical investigation with an investigational drug within 1 month prior to screening or within 5 half-lives of the investigational treatment whichever is longer.\n* Patients with concomitant treatment of strong CYP3A4 inducers or inhibitors.\n* Patients who have received pituitary irradiation within the last 5 years prior to the baseline visit\n* Patients with known hepatitis B surface antigen (HbsAg) positivity\n* Patients with known hepatitis C antibody (anti-HCV) positivity",{"count":548,"type":22},20,[241],"Supported by the pre-clinical data (summarized in Research Strategy), the investigators propose that Fimepinostat is an ideal candidate drug in the treatment and intervention of patients with Cushing Disease. The investigators propose a pilot, short-term (4 weeks) phase II single-center study to demonstrate the safety and efficacy of Fimepinostat in the treatment of patients with de novo, persistent, and\u002For recurrent CD recruited at the University of California, Los Angeles. The trial will have a 2-arm design and will simultaneously examine two different doses of Fimepinostat. The study will allow the investigators to determine the efficacy and safety of these doses in the treatment of CD and guide dose selection for subsequent, larger studies. Funding Source - FDA OOPD.",[552],"Cushing Disease",{"date":513,"type":38},{"date":555,"type":38},"2025-01-16",{"date":557,"type":22},"2029-01",{"name":44,"class":45},{"id":560,"slug":561,"hasResults":12,"nctId":562,"briefTitle":563,"officialTitle":563,"acronym":564,"eligibilityCriteria":565,"healthyVolunteers":12,"sex":18,"minAge":566,"maxAge":567,"enrollmentInfo":568,"targetDuration":4,"studyType":23,"phases":569,"briefSummary":570,"conditions":571,"keywords":574,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":578,"lastUpdatePostDateStruct":579,"startDateStruct":580,"completionDateStruct":582,"leadSponsor":583,"locationsCount":46},"100581196","trigeminal-nerve-stimulation-for-children-with-prenatal-alcohol-exposure-100581196","NCT06847165","Trigeminal Nerve Stimulation for Children With Prenatal Alcohol Exposure","TNS-PAE","Inclusion Criteria:\n\n* \\- Fetal alcohol syndrome, partial fetal alcohol syndrome, or alcohol-related neurodevelopmental disorder per modified Institute of Medicine criteria (thus positive maternal drinking in pregnancy required, facial stigmata not required)\n* Prenatal alcohol exposure (PAE) \\>6 drinks\u002Fweek for \\>= 2 weeks and\u002For \\>= 3 drinks on \\>= 2 occasions throughout gestation per Health Interview for Women\u002FHealth Interview for Adoptive and Foster Parents (HIW\u002FHIAFP)\n* Diagnosis of Diagnostic and Statistical Manual 5th edition (DSM-5) attention deficit hyperactivity disorder (ADHD), including problems with inattention, hyperactivity, impulsivity, and\u002For executive function. Screening for ADHD will be done using the Swanson, Nolan, and Pelham Teacher and Parent Rating Scale (SNAP IV). Formal diagnosis of ADHD will be based on the Mini-International Neuropsychiatric Interview for Children and Adolescents (MINI-KID) with input from the Behavior Rating of Executive Function (BRIEF II) and the Conners 4.\n* Parent and child able to complete testing in English\n* Child able to cooperate during MRI\n* Full-Scale Intelligence Quotient \\>70 per the Kaufman Brief Intelligence Test (K-BIT-2)\n* Child able to comply with study procedures\n* Age 8-12\n\nExclusion Criteria:\n\n* \\- Other toxic exposure per HIW\u002FHIAFP whose influence clearly surpasses that of alcohol (very rare) per study clinician judgement\n* Known genetic syndrome associated with ADHD-like symptoms including fragile X, tuberous sclerosis, or generalized resistance to thyroid hormone\n* Serious medical or neurologic illness likely to influence brain function, e.g., seizures, closed-head trauma\n* Gestation \\\u003C 34 weeks\n* Ferromagnetic metal, claustrophobia, or other MRI or TNS contraindication (e.g., insulin pumps or other body-worn devices)\n* Diagnosis of autism spectrum disorder, psychotic disorder, or major mood disorder\n* Active suicidal ideation as evidenced by meeting criteria for \"Current\" or \"Lifetime attempt\" on the Suicidality module or \"Current' or 'In early remission' on the Suicide Behavior Disorder module of the MINI KID","8 Years","12 Years",{"count":212,"type":22},[25],"This is an open-label trial of trigeminal nerve stimulation (TNS) for children aged 8-12 years with attention deficit hyperactivity disorder (ADHD) putatively due to prenatal alcohol exposure (PAE). TNS has been successful in treating pediatric ADHD generally and it is US Food and Drug Administration (FDA)-cleared for this condition. But this will be the first time it is tried for ADHD specifically associated with PAE. In TNS, a weak electric current is applied to the child's forehead overnight while sleeping to gently stimulate the brain. TNS is administered at home by the parent to the child. TNS is safe and well tolerated. Efficacy of TNS in ADHD is \\~50%. The purpose of the present pilot study is to determine the feasibility of TNS for children with PAE and ADHD. Feasibility means safety (any serious side effects?), tolerability (do children comply with TNS? are they comfortable with it?), and a rough idea of efficacy (does TNS seem to work in most kids?) A secondary goal of the study is to get a more precise idea of brain mechanisms of TNS with magnetic resonance imaging (MRI). Families who participate will make three clinic visits: eligibility (4-5 hours), pre-TNS (2-3 hours including MRI), and post-TNS (2-3 hours including MRI). Children will receive TNS, applied by the parent, for 8 hours every night while sleeping for 4 weeks. Four weeks after treatment, families will take part in a telephone follow-up, to see whether any improvements made last.",[572,573],"Fetal Alcohol Spectrum Disorders","Attention Deficit Hyperactivity Disorder",[575,576,577],"prenatal alcohol exposure","attention deficit hyperactivity disorder","trigeminal nerve stimulation","2026-07-14",{"date":536,"type":38},{"date":581,"type":38},"2025-04-26",{"date":333,"type":22},{"name":44,"class":45},{"id":585,"slug":586,"hasResults":12,"nctId":587,"briefTitle":588,"officialTitle":588,"acronym":4,"eligibilityCriteria":589,"healthyVolunteers":17,"sex":18,"minAge":590,"maxAge":591,"enrollmentInfo":592,"targetDuration":4,"studyType":23,"phases":593,"briefSummary":594,"conditions":595,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":578,"lastUpdatePostDateStruct":597,"startDateStruct":598,"completionDateStruct":600,"leadSponsor":602,"locationsCount":46},"100551348","social-facilitation-of-emotion-regulation-in-adolescence-100551348","NCT06458920","Social Facilitation of Emotion Regulation in Adolescence","Inclusion Criteria:\n\n* Adolescent participants must be 13-15 year of age\n* Adult participants must be 20-25 years of age\n* Proficient in English\n\nExclusion Criteria:\n\n* Auditory, visual or cognitive impairment\n* Any health conditions that are contraindicated for MRI","13 Years","25 Years",{"count":162,"type":22},[25],"The goal of this project is to test whether regulating emotions with help from a friend is more effective and long-lasting in adolescents than regulating alone, and to characterize age-related differences in the neural mechanisms supporting social versus cognitive emotion regulation. Participants will complete a psychology experiment while undergoing fMRI scanning.",[596],"Emotion Regulation",{"date":536,"type":38},{"date":599,"type":38},"2022-10-05",{"date":601,"type":22},"2026-10-01",{"name":44,"class":45},{"id":604,"slug":605,"hasResults":12,"nctId":606,"briefTitle":607,"officialTitle":607,"acronym":4,"eligibilityCriteria":608,"healthyVolunteers":17,"sex":18,"minAge":160,"maxAge":4,"enrollmentInfo":609,"targetDuration":4,"studyType":23,"phases":611,"briefSummary":613,"conditions":614,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":616,"lastUpdatePostDateStruct":617,"startDateStruct":618,"completionDateStruct":620,"leadSponsor":622,"locationsCount":46},"100479562","phase-1-writing-about-experiences-and-health-in-older-adults-ii-100479562","NCT05524597","Writing About Experiences and Health in Older Adults II","Inclusion Criteria:\n\n* Healthy adults age 65 years and older\n\nExclusion Criteria:\n\n1. current smokers\n2. active, uncontrolled medical disorders\n3. chronic infection (e.g., Hepatitis C, HIV)\n4. use of certain medications (steroid use, opioid use)\n5. psychiatric disorders (e.g., current major depression, bipolar disorder)\n6. body mass index (BMI) greater than 35\n7. left-handed\n8. claustrophobic\n9. metal in body\n\nOther exclusion criteria may apply.",{"count":610,"type":22},200,[612],"PHASE1","UCLA researchers looking for healthy older adults (aged 65+) to participate in a study investigating how writing about experiences can affect your brain and body.\n\nOnce a week for 6 weeks, participants will write about their experiences and fill out online questionnaires. Participants will also come to the UCLA campus to complete a neuroimaging session (fMRI), provide a blood spot sample, and fill out questionnaires 2 times: once prior to the 6-week writing period and once immediately after the 6-week writing period.",[615],"Social Psychology","2026-07-13",{"date":578,"type":38},{"date":619,"type":38},"2023-03-13",{"date":621,"type":22},"2026-12",{"name":44,"class":45},""]